Kết quả điều trị ung thư buồng trứng kháng platinum bằng gemcitabine tại bệnh viện Ung Bướu Hà Nội=Gemcitabine treatment outcome of patients with platinum–resistant ovarian cancer at Hanoi Oncology hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Bích Hợp Hán, Duy Khoa Nguyễn, Thị Phương Anh Nguyễn, Thị Kiều Oanh Trương, Ngọc Dương Vũ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.106-115

Bộ sưu tập: Metadata

ID: 478122

Thêm vào giỏ

Đánh giá kết quả điều trị bệnh nhân ung thư biểu mô buồng trứng kháng platinum bằng gemcitabine tại bệnh viện Ung Bướu Hà Nội và một số tác dụng không mong muốn của phác đồ. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu kết hợp tiến cứu trên bệnh nhân ung thư biểu mô buồng trứng kháng platinum, được điều trị bằng phác đồ gemcitabine tại bệnh viện Ung Bướu Hà Nội từ 2017 đến tháng 6 năm 2023. Đáp ứng điều trị, một số tác dụng phụ và sống thêm của bệnh nhân được ghi nhận. Kết quả: Có 42 bệnh nhân đủ điều kiện tham gia nghiên cứu. Độ tuổi hay gặp nhất trong nghiên cứu là 50-70 tuổi chiếm 76,2%. (32/42) 20/42 (47,6%) bệnh nhân tiến triển trong khi điều trị platinum. Có 31/42 (73,8%) bệnh nhân được điều trị gemcitabine là lựa chọn đầu tiên khi kháng platinum. Tỉ lệ đáp ứng của phác đồ là 31% (13/42). Trung vị thời gian sống thêm bệnh không tiến triển (PFS) là 4,4 tháng, trung vị thời gian sống thêm toàn bộ (OS) là 11,6 tháng. Các tác dung phụ hay gặp bao gồm hạ huyết sắc tố ở 37/42 (88,1%) bệnh nhân, hạ bạch cầu trung tính ở 25/42 (61,9%) bệnh nhân, hạ tiểu cầu gặp ở 17/42 (40,5%) bệnh nhân và chủ yếu gặp ở độ I, II. Kết luận: Gemcitabine là phác đồ hiệu quả và an toàn cho các bệnh nhân ung thư biểu mô buồng trứng kháng platinum.To evaluate the gemcitabine treatment outcome and side effects on patients with platinum–resistant ovarian cancer at Ha Noi Oncology Hospital. Patients and Methods: A retrospective and prospective descriptive study was conducted on patients with platinum-resistant epithelial ovarian cancer treated with gemcitabine at Hanoi Oncology Hospital from 2017 to June 2023. Treatment response, certain side effects, and patients’ survival were recorded. Results: There were 42 eligible patients enrolled. The most common age group was 50-70 years old, accounting for 76.2%. 20/42 (47.6%) patients progressed while on platinum therapy
31/42 (73.8%) patients received gemcitabine as the first-line treatment for platinum resistance. The overall response rate (ORR) was 31% (13/42). The median progression-free survival (PFS) was 4.4 months, and the median overallfree survival (OS) was 11.6 months. Common side effects included anemia, occurring in 37/42 (88.1%) patients, neutropenia in 25/42 (61.9%) patients, and thrombocytopenia in 17/42 (40.5%) patients, and all were mainly at grades I and II. Conclusion: Gemcitabine is an effective and safe regimen in platinum-resistant ovarian cancer.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR